Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Cancer immunotherapy has revolutionized the way we approach the treatment of malignancies, focusing on harnessing the body's immune system to specifically target and destroy tumor cells. A critical aspect of successful immunotherapy is the ability to present a broad spectrum of tumor antigens to the immune system. Traditional cancer vaccines often present limited sets of antigens, which may not fully engage the immune system or provide long-lasting protection. The Tumor Lysate Pulsed Dendritic Cell (DC) Development Service addresses this challenge by utilizing tumor lysates to load dendritic cells with a comprehensive range of tumor-specific antigens, providing an optimal strategy for immune activation and tumor recognition.
Dendritic cells (DCs) are highly specialized immune cells responsible for presenting antigens to T-cells and triggering specific immune responses. By loading dendritic cells with tumor lysates, which contain both surface and intracellular tumor antigens, we enhance their ability to stimulate immune cells and produce a robust, multi-faceted immune response. This service is designed to ensure the effective presentation of tumor-associated antigens (TAAs) and increase the immune system's ability to recognize and destroy cancer cells, providing a more effective cancer immunotherapy approach.
Our Tumor Lysate Pulsed Dendritic Cell (DC) Development Service offers a comprehensive solution for generating tumor-specific immune responses by pulsing dendritic cells with tumor lysates. This process significantly expands the range of tumor antigens presented to the immune system, ensuring a more targeted and potent immune activation.
Key steps involved in our service include:
Tumor lysates are derived from patient-specific tumor samples or allogeneic tumor sources. These lysates contain both cell surface antigens and intracellular tumor antigens, providing a diverse array of targets for the immune system. The tumor cells are carefully lysed to release their full antigenic profile without compromising the integrity of the antigens.
Dendritic cells are isolated from peripheral blood or other sources and cultured under conditions that promote their maturation. Mature dendritic cells are equipped to efficiently process and present antigens to T-cells, ensuring effective immune activation.
The tumor lysates are introduced to the mature dendritic cells, allowing them to internalize and process a broad spectrum of tumor-associated antigens. This step enhances the dendritic cells' ability to present these antigens to both CD4+ helper T cells and CD8+ cytotoxic T cells, thereby improving immune recognition of the tumor.
After pulsing, the dendritic cells are thoroughly tested to ensure that they effectively present the tumor antigens and activate T-cell responses. The hybrid cells are also assessed for their viability and functionality before being used in therapeutic applications.
The tumor lysate pulsed dendritic cells can be tailored to the unique characteristics of the patient's tumor, ensuring that the most relevant antigens are presented to maximize the immune response. This ensures that the immunotherapy is highly personalized and optimized for the individual.
Tumor lysates contain a wide variety of tumor-associated antigens, including both surface and intracellular proteins. This comprehensive antigen pool ensures that the dendritic cells are able to present multiple targets, leading to a more robust immune activation.
By using dendritic cells to present a broader range of antigens, we enhance both the innate and adaptive immune responses. This leads to the activation of CD4+ T cells, which help coordinate the immune response, as well as CD8+ cytotoxic T cells that directly target and destroy cancer cells.
Our service is highly customizable, enabling us to tailor the tumor lysate pulsed dendritic cells to the specific antigens expressed by the patient's tumor. This personalized approach maximizes the effectiveness of the immune response and ensures the therapy is optimally targeted.
Creative Biolabs uses advanced technologies and expertise in dendritic cell biology to deliver a high-quality, effective service. Our commitment to excellence ensures that our tumor lysate pulsed dendritic cells meet the highest standards of quality and functionality.
The tumor lysate pulsed dendritic cells can be used in various immunotherapeutic applications, including personalized cancer vaccines, immune-based therapies, and adoptive T-cell transfer, providing a flexible approach to cancer treatment.
Q1. What is a tumor lysate and how is it used in this service?
A1: tumor lysate is a mixture of proteins, peptides, and other antigens released from tumor cells when they are lysed (broken down). These lysates contain a wide variety of tumor-specific antigens, including both membrane-bound and intracellular proteins, which can be used to stimulate a broad immune response when presented to dendritic cells.
Q2. How do dendritic cells contribute to cancer immunotherapy?
A2: Dendritic cells are key players in the immune system. They process and present antigens to T-cells, effectively activating the immune response. By loading dendritic cells with tumor lysates, we enhance their ability to present a comprehensive range of tumor antigens, improving the immune system's ability to recognize and destroy cancer cells.
Q3. Can this service be customized for different types of cancer?
A3: Yes, the service is highly customizable. We can use tumor lysates from specific tumor types, tailoring the dendritic cell pulsing process to present the most relevant antigens for that particular cancer. This ensures a targeted and personalized immune response.
Creative Biolabs is committed to providing innovative and personalized immunotherapy solutions through our Tumor Lysate Pulsed Dendritic Cell (DC) Development Service. If you would like to learn more about how this service can be applied to your cancer immunotherapy research or development needs, please contact us.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
